Seaport Therapeutics Winds Up USD 225Mn Series B Financing Round
Seaport Therapeutics, (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, recently announced the closing of an oversubscribed $225 million Series B financing round. According to Industry sources, this syndicate was powered by General Atlantic, a leading global growth investor, with participation from funds […]